However, few studies have provided follow-up information on the relationship between COX-2 positivity in DCIS and disease progression after treatment, and none have explored whether NSAID use modulates the risk of progression (Kulkarni et al, 2008; Kerlikowske et al, 2010). Here, PTGS2 is linked to ductal breast carcinoma in situ.